The identification of an orally active, nonpeptide bradykinin B2 receptor antagonist, FR173657

British Journal of Pharmacology

Volumn 120, Issue 4, 1997, Pages 617-624

  Asano, Masayuki ^a   Inamura, Noriaki ^a   Hatori, Chie ^a   Sawai, Hiroe ^a   Fujiwara, Tatsujiro ^a   Katayama, Akira ^a   Kayakiri, Hiroshi ^a   Satoh, Shigeki ^a   Abe, Yoshito ^a   Inoue, Takayuki ^a   Sawada, Yuki ^a   Nakahara, Kunio ^a   Oku, Teruo ^a   Okuhara, Masakuni ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Antagonist; B2 receptor; Bradykinin; FR173657; Nonpeptide; Orally active

Indexed keywords

3 (6 ACETAMIDO 3 PYRIDYL) N [N [2,4 DICHLORO 3 [(2 METHYL 8 QUINOLINYL)OXYMETHYL]PHENYL] N METHYLAMINOCARBONYLMETHYL]ACRYLAMIDE; ACETYLCHOLINE; BRADYKININ ANTAGONIST; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; HISTAMINE; KALLIDIN DERIVATIVE; RADIOLIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHOSPASM; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; GUINEA PIG; HUMAN; HUMAN CELL; ILEUM; LUNG FIBROBLAST; MALE; MEMBRANE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; UTERUS;

ADMINISTRATION, ORAL; ANIMALS; BRADYKININ; BRONCHOCONSTRICTION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GUINEA PIGS; HUMANS; ILEUM; INFLAMMATION; MALE; MUSCLE, SMOOTH; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, BRADYKININ B2; RECEPTORS, BRADYKININ; UTERUS;

EID: 8044243585     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0700955     Document Type: Article

References (51)

1. AMBAR, I., KLOOG, Y., SCHVARTZ, I., HAZUM, E. & SOKOLOVSKY, M. (1989). Competitive interaction between endothelin and sarafotoxin: Binding and phosphoinositides hydrolysis in rat atria and brain. Biochem. Biophs. Res. Commun., 158, 195-201.
2. ARMSTRONG, D., JEPSON, J.B., KEELE, C.A. & STEWART, J.M. (1957). Pain producing substance in human inflammatory exudates and plasma. J. Physiol., 135, 350-370.
3. ASANO, M., INAMURA, N., NAKAHARA, K., NAGAYOSHI, A., ISONO, T., HAMADA, K., OKU, T., NOTSU, Y., KOHSAKA, M. & ONO, T. (1992). A 5-lipoxygenase inhibitor, FR110302, suppresses airway hyperresponsiveness and lung eosinophilia induced by sephadex particles in rats. Agents Actions, 36, 215-221.
4. 2 bradykinin receptors with nanomolar affinity expressed in passaged IMR90 human lung fibroblasts. Eur. J. Cell Biol., 58, 71-80.
5. BARNES, P.J., CHUNG, F. & PAGE, C.P. (1988). Inflammatory mediators and asthma. Pharmacol. Rev., 40, 49-83.
6. BHOOLA, K.D., FIGUEROA, C.D. & WORTHY, K. (1992). Bioregulation of kinins: Kallikreins, kininogens, and kininases. Pharmacol. Rev., 44, 1-80.
7. BRAMLEY, A.M., SAMHOUN, M.N. & PIPER, P.J. (1990). The role of the epithelium in modulating the responses of guinea-pig trachea induced by bradykinin in vitro Br. J. Pharmacol., 99, 762-766.
8. 3H]-NECA in rat striatal membranes. Mol. Pharmacol., 29, 331-346.
9. 2. Proc. Natl. Acad. Sci. U.S.A., 85, 6374-6378.
10. BURCH, R.M., FARMER, S.G. & STERANKA, L.R. (1990). Bradykinin receptor antagonists. Med. Res. Rev., 10, 237-269.
11. CHERONIS, J.C., WHALLEY, E.T., NGUYEN, K.T., EUBANKS, S.R., ALLEN, L.G., DUGGAN, M.J. LOY, S.D. BONHAM, K.A. & BLODGETT, J.K. (1992). A new class of bradykinin antagonists: synthesis and in vitro activity of bissuccinimidoalkane peptide dimers. J. Med. Chem., 35, 1563-1572.
12. CHRISTIANSEN, S.C., PROUD, D. & COCHRANE, C.G. (1987). Detection of tissue kallikrein in bronchoalveolar lavage fluid of asthmatic subjects. J. Clin. Invest., 79, 188-197.
13. COSTELLO, A.H. & HARGREAVES, K.M. (1989). Suppression of carrageenin-induced hyperalgesia, hyperthermia and oedema by a bradykinin antagonist. Eur. J. Pharmacol., 171, 259-263.
14. DRAY, A., BETTANEY, J., FORSTER, P. & PERKINS, M.N. (1988). Activation of a bradykinin receptor in peripheral nerve and spinal cord in the neonatal rat in vitro. Br. J. Pharmacol., 95, 1008-1010.
15. FARMER, S.G. (1991). Role of kinins in airway diseases. Immunopharmacology, 22, 1-20.
16. 8]bradykinin) in different in vivo animal models of inflammation. J. Pharmacol. Exp. Ther., 273, 1078-1084.
17. 2 receptor antagonist, in vitro and in vivo. J. Pharmacol. Exp. Ther., 273, 1071-1077.
18. FULLER, R.W., DIXON, C.M.S., CUSS, F.M.C. & BARNES, P.J. (1987). Bradykinin-induced bronchoconstriction in humans. Am. Rev. Respir. Dis., 135, 176-180.
19. HAAKSMA, E.E., LEURS, R. & TIMMERMAN, H. (1990). Histamine receptors: subclasses and specific ligands. Pharmacol. Ther., 47, 73-104.
20. HARGREAVES, K.M., TROULLOS, E.S., DIONNE, R.A., SCHMIDT, E.A., SCHAFER, S.C. & JORIS, J.L. (1988). Bradykinin is increased during acute and chronic inflammation: Therapeutic implications. Clin. Pharmacol. Ther., 44, 613-621.
21. HEAPY, C.G., SHAW, J.S. & FARMER, S.C. (1993). Differential sensitivity of antinociceptive assays to the bradykinin antagonist Hoe 140. Br. J. Pharmacol., 108, 209-213.
22. HESS, J.F., BORKOWSKI, J.A., YOUNG, G.S., STRADER, C.D. & RANSOM, R.W. (1992). Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor. Biochem. Biophys. Res. Commun., 184, 260-268.
23. HOCK, F.J., WIRTH, K., ALBUS, U., LINZ, W., GERHARDS, H.J., WIEMER, G., HENKE, S., BREIPOHL, G., KÖNIG, W., KNOLLE, J. & SCHÖLKENS, B.A. (1991). Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br. J. Pharmacol., 102, 769-773.
24. ICHINOSE, M., BELVISI, M.G. & BARNES, P.J. (1990). Bradykinin-induced bronchoconstriction in guinea pig in vivo: role of neural mechanims. J. Pharmacol. Exp. Ther., 253, 594-599.
25. ISHIZAKA, S.T., IWATA, M. & ISHIZAKA, K. (1985). Release of histamine and arachidonate from mouse mast cells induced by glycosylation-enhancing factor and bradykinin. J. Immunol., 134, 1880-1887.
26. 2 receptors isolated by receptor-specific monoclonal antibodies are tyrosine phosphorylated. Proc. Natl. Acad. Sci. U.S.A., 90, 10994-10998.
27. 3H]Quinuclidinylbenzilate binding to muscarinic cholinergic receptors in rat brain. J. Pharmacol. Exp. Ther., 228, 648-655.
28. MANNING, D.C., RAJA, S.N., MEYER, R.A. & CAMPBELL, J.N. (1991). Pain and hyperalgesia after intradermal injection of bradykinin in humans. Clin. Pharmacol. Ther., 50, 721-729.
29. MANNING, D.C., VAVREK, R., STEWART, J.M. & SYNDER, S.H. (1986). Two bradykinin binding sites with picomolar affinities. J. Pharmacol. Exp. Ther., 237, 504-512.
30. McLEAN, S., GANONG, A., SEYMOUR, P.A., SNIDER, R.M., DESAI, M.C. & ROSEN, T. (1993). Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin NK-1 receptor. J. Pharmacol. Exp. Ther., 267, 472-479.
31. 1 bradykinin receptor. J. Biol. Chem., 269, 21583-21586.
32. MIZUMURA, K., MINAGAWA, M., TSUJII, T. & KUMAZAWA, T. (1990). The effects of bradykinin agonists and antagonists on visceral polymodal receptor activities. Pain, 40, 221-227.
33. 4 binding to guinea-pig lung membranes. The correlation of binding affinity with activity on the guinea-pig ileum. Eur. J. Pharmacol., 182, 301-312.
34. 8J-BK and HOE 140, in two models of persistent hyperalgesia in the rat. Pain, 53, 191-197.
35. 1 receptors in vivo in a model of ultra-violet irradiation-induced thermal hyperalgesia in rat. Br. J. Pharmacol., 110, 1441-1444.
36. PROUD, D. & KAPLAN, A. (1988). Kinin formation: mechanisms and role in inflammatory disorders. Ann. Rev. Immunol., 6, 49-83.
37. RANG, H.P., BEVAN, S. & DRAY, A. (1991). Chemical activation of nociceptive peripheral neurons. Br. Med. Bull., 47, 534-548.
38. 3H]Idazoxan. J. Neural. Transm., 68, 79-95.
39. REGOLI, D. & BARABÉ, J. (1980). Pharmacology of bradykinin and related peptides. Pharmacol. Rev., 32, 1-46.
40. ROBERTS, R.A. & GULLICK, W.J. (1989). Bradykinin receptor number and sensitivity to ligand stimulation of mitogenesis is increased by expression of a mutant ras oncogene. J. Cell Sci., 94, 527-535.
41. 2 receptor. J. Med. Chem., 36, 2583-2584.
42. SARIA, A., MARTLING, C.R., YAN, Z., THEODORSSON NORHEIM, E., GAMSE, R. & LUNDBERG, J.M. (1988). Release of multiple tachykinins from capsaicin-sensitive sensory nerves in the lung by bradykinin, histamine, dimethylphenyl piperazinium, and vagal nerve stimulation. Am. Rev. Respir. Dis., 137, 1330-1335.
43. 2+ efflux by D-Phe substituted bradykinin analogues. Eur. J. Pharmacol., 227, 309-315.
44. 2 receptor antagonist. Proc. Natl. Acad. Sci. U.S.A., 91, 4693-4697.
45. 2, a new scale for the measurement of drug antagonism. Br. J. Pharmacol., 2, 189-206.
46. STERANKA, L.R., MANNING, D.C., DE HAAS, C.J., FERKANY, J.W. & BOROSKY, S.A. (1988). Bradykinin as pain mediator: receptors are localized to sensory neurones, and antagonists have analgesic actions. Proc. Natl. Acad. Sci. U.S.A., 85, 3245-3249.
47. STEWART, J.M. (1995). Bradykinin antagonists: development and applications. Biopolymers, 37, 143-155.
48. VAVREK, R. & STEWART, J.M. (1985). Competitive antagonists of bradykinin. Peptides, 6, 161-164.
49. WHALLEY, E.T., CLEGG, S., STEWART, J.M. & VAVREK, R.J. (1987). The effect of kinin agonists and antagonists on the pain response of the human blister base. Naunyn-Schmiedeberg's Arch. Pharmacol., 336, 652-655.
50. WINTER, C.A., RISLEY, E.A. & NUSS, G.W. (1962). Carrageenin-induced oedema in hind paw of the rat as an assay for antiinflammatory drugs. Proc. Soc. Exp. Biol., 111, 544-547.
51. WIRTH, K., HOCK, F.J., ALBUS, U., LINZ, W., ALPERMANN, H.G., ANAGNOSTOPOULOS, H., HENK, S., BREIPOHL, G., KÖNIG, W., KNOLLE, J. & SCHÖLKENS, B.A. (1991). Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br. J. Pharmacol., 102, 774-777.